{"id":"W4376272391","doi":"10.1016/j.annonc.2023.05.002","title":"A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; Western University; Princess Margaret Cancer Centre","funders":"Comprehensive Cancer Center, University of Chicago Medical Center; National Cancer Institute; Astellas Pharma; Celgene; AstraZeneca; University of Chicago; Pfizer","keywords":"Medicine; Lenalidomide; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Refractory (planetary science); Adverse effect; Progression-free survival; Thyroid cancer; Gastroenterology; Randomized controlled trial; Surgery; Clinical trial; Cancer; Chemotherapy; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002146929,0.001789545,0.00356345,0.000522129,0.0007130832,0.00164911,0.001566255,0.001689618,0.00454898],"category_scores_gemma":[0.00191116,0.0009563467,0.001829018,0.0005772526,0.002014325,0.001453101,0.0005020593,0.004349533,0.0009804771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001704959,"about_ca_system_score_gemma":0.002618392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002733955,"about_ca_topic_score_gemma":0.006921027,"domain_scores_codex":[0.9991578,0.0004148429,0.00004798227,0.0001549818,0.00007336959,0.0001510066],"domain_scores_gemma":[0.9987509,0.0003200083,0.0001924392,0.0001231811,0.00007282258,0.0005405511],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9645255,0.01589367,0.0009452516,0.0003038939,0.001152167,0.00004333402,0.00008875494,0.0004122042,0.003829343,0.0001316287,0.0006789684,0.01199535],"study_design_scores_gemma":[0.9533349,0.04435996,0.00107641,0.00001016886,0.0002750642,0.000022451,0.00002717939,0.0002260158,0.0002174937,0.00007364593,0.0003648971,0.00001185066],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907923,0.002594577,0.0005393333,0.0005179525,0.0004004947,0.002738509,0.0007098623,0.0000757037,0.001631363],"genre_scores_gemma":[0.9891334,0.001928313,0.0017639,0.001139205,0.0003422817,0.002554164,0.001113753,0.00003212743,0.001992718],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00454898,"threshold_uncertainty_score":0.01521778,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1684255401910898,"score_gpt":0.4695767661730993,"score_spread":0.3011512259820095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}